Amporin Pharmaceuticals aims to develop a new class of small-molecule drugs that block and eliminate toxic soluble oligomers and pores from within cell membranes.
Amporin Pharmaceuticals has raised €157k across 1 funding round from 1 investor, most recently a round in Jul 2024. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-07-25 | Other |
| €157k |
| Venture Kick |
| View deal → |
